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Background: Among the most important causes of illness and death in both pregnant women and their newborn
infants are respiratory infections including influenza. Pregnant women in North America have a 4 to 5 fold excess rate
of hospitalization compared to non-pregnant women. Rates of infant hospitalization associated with influenza are
much higher than in their mothers. Fully half of children hospitalized for influenza in the US are in the age group 0–5
months, a group where no vaccine is licensed. Data on influenza are much fewer in low income countries where the
risks of serious morbidity and mortality are much higher. A recent trial in Bangladesh suggested that influenza
immunization in pregnant women could have important protective effects against influenza in both mothers and
their infants. These trials were designed to provide additional evidence about the effect of influenza vaccination in
pregnancy in settings where influenza may circulate for up to ten months/year.
Methods/Design: We conducted a consecutive pair of community-based, placebo-controlled, randomized trials
of influenza vaccination of pregnant women in a rural district in southern Nepal. Two trials were conducted
to insure, as much as possible, the match of circulating strains with those included in the vaccine. Eligible
women included all who were or became pregnant over a one year period. Each trial included a one year
cohort of pregnant women who were individually randomized to the influenza vaccine available at the time
of their enrollment or placebo. Exclusions included a history of allergy to vaccine components, prior influenza
vaccine receipt, and for the second trial, participation in the first trial. Morbidity was assessed on a weekly
basis for women throughout pregnancy and through 180 days post-partum. Infants were followed weekly
through 180 days. Primary outcomes included: 1) incidence of influenza like illness in women, 2) incidence of
laboratory confirmed influenza illness in infants, and 3) birthweight among newborn infants.
Discussion: We have presented the design and methods of two randomized trials of influenza immunization
of pregnant women.
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Pregnancy and delivery are hazardous for mothers and
infants in low resource regions, with rates of illness
and death many times higher than in wealthier re-
gions. Among the most important causes of these ill-
nesses and deaths in both mothers and infants are
respiratory infections including influenza [1]. The best
estimates of the clinical significance of complications
of respiratory disease during pregnancy are based on
indirect data from developed countries [2]. Remark-
ably few data exist on the prevalence or significance
of laboratory-proven influenza infections in pregnant
women and the outcomes of infection with influenza
in the woman and her fetus, particularly in developing
countries [3]. The increased risk of influenza in preg-
nant women is related to physiologic changes includ-
ing increases in blood volume, decreases in lung
capacity, and attenuation of cell-mediated immune re-
sponses [4]. Excess mortality with rates approaching
50% were reported in pregnant women during the
1918–19 influenza pandemic, some of the highest
rates of any patient group. Influenza was also a lead-
ing cause of maternal mortality during the 1957 pan-
demic [5] and an important cause of maternal
morbidity and mortality during the 2009–10 influenza
A/H1N1 pandemic [6]. The impact of influenza on
the fetus when influenza is contracted during preg-
nancy is less clear, although cases of stillbirths and
fetal deaths have been reported [7] and increased rates
of prematurity were documented in the most recent
pandemic [8].
A case–control study of US women showed that
healthy pregnant women have a four-fold increased rate
of hospitalization during influenza season compared to
post-partum controls [9]. This indirect evidence has
been validated by several studies in the United States
and, most recently, by studies in Canada that show a
five-fold seasonal increase in the risk of hospitalization
among pregnant women [10-12]. Limited data exist doc-
umenting influenza infection in pregnant women using
laboratory methods, although a study from Britain
showed serologic evidence of influenza infection during
pregnancy in 11% of 1,659 pregnant women, associated
with an overall 43% increased rate of complications in
the delivery, postpartum, or newborn infant periods,
when compared to uninfected controls [3]. A study of
over 6 million hospital admissions of pregnant US
women showed that hospitalization with a respiratory
illness during pregnancy in influenza season was associ-
ated with 4-fold increased risk of preterm delivery and
cesarean section, and a 2.5-fold increase in reports of
fetal distress, compared to hospitalizations without a
respiratory illness [13]. Because of the increased risk of
hospitalization, and proven safety of influenza vaccine inpregnant women, routine immunization of all pregnant
women during influenza season has been recommended
in the US since 1997, and by WHO since 2005.
US infants and children have relatively high rates of ill-
ness and hospitalization for influenza infection, despite
increasing availability of laboratory diagnostics and the
availability of licensed influenza vaccine for this age
group [14]. The high rates of illness and hospitalization
rates of ~1/1000 prompted the US recommendations in
2004 for universal immunization of infants from 6–59
months. More recently, it has become clear that US
infants from 0–5 months of age have a substantial bur-
den of influenza, with hospitalization rates of 0.8 to 1.2%
[7,14]. These rates of young infant hospitalization are
higher than in other recognized high-risk groups for
influenza, such as adults over 60, and much higher than
in their mothers. Of all US children under five years of
age hospitalized for proven influenza, approximately
50% are in the age group 0–5 months [15], an age group
where licensed influenza vaccine is not available. In
addition, medically attended illness rates attributable to
influenza are 50–100 fold higher than the influenza
hospitalization rates in this young infant group [9,14].
Maternal immunization to protect both mothers and
their young infants is currently recommended to prevent
neonatal tetanus (in limited resource regions) and influ-
enza (in the US, UK, and Canada) [15]. While maternal
immunization is a safe and effective strategy with potential
to advance both Millennium Development Goals 4 and 5
(child and maternal mortality, respectively), this approach
remains underutilized in limited resource regions to pre-
vent illness in mothers and infants [16]. Because the deliv-
ery system of antenatal immunization is in place for
tetanus toxoid in many low-resource regions, the maternal
immunization strategy is programmatically feasible and
sustainable for other vaccines [17].
Vaccines with potential to reduce illness of both
mothers and infants include influenza, pertussis, and
pneumococcal vaccines. These vaccines are known a) to
be safe in pregnant women, b) to elicit functional antibody
during the period of high risk in mothers, which can then
be transferred to the fetus c) deliverable in existing ante-
natal tetanus toxoid programs, and d) relatively low cost
[12]. A recent comparative trial of trivalent inactivated
influenza vaccine (TIV) and pneumococcal polysaccharide
vaccines in pregnant women in Bangladesh showed sub-
stantial protection of both mothers and their infants by
maternal immunization with TIV. Maternal influenza
immunization reduced laboratory-proven influenza in
their infants by 68% from birth to six months of age, and
also reduced episodes of maternal influenza-like illnesses
(ILI) by 35% [18]. In addition, there were significant im-
provements in birthweight associated with receipt of influ-
enza vaccine in pregnancy [19]. However, the Bangladesh
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address the impact of maternal influenza vaccine. There-
fore, additional studies to answer this question in a variety




Two, consecutive, individually randomized, placebo con-
trolled trials of influenza immunization during preg-
nancy were conducted in southern Nepal. Each trial
recruited a population-based cohort of pregnant women
who were between 17 and 34 weeks gestation over a one
year period. The choice of two independent cohorts was
used to insure, as much as possible, there would be a
match between circulating strains of influenza and that
year’s vaccine strains. Two additional substudies were
also conducted during these randomized, controlled
trials. The first was conducted in a subsample of
mother/infant pairs in both trials and assessed the
degree to which influenza vaccine produced vaccine-
specific antibody in the mothers and the level of anti-
body transferred to her infant as measured in umbilical
cord blood and breast milk. The second was done in a
subsample during the first trial and determined the im-
pact of maternal influenza immunization on indirect
protection from ILI and laboratory confirmed influenza
disease among other household members.
Study population
The study population for these trials included all
married women between 15 and 40 years of age who
were identified as pregnant with gestational age be-
tween 17 and 34 weeks during a 12-month period in
9 Village Development Committees (VDCs) of Sarlahi
District in the terai region of southern Nepal. The
terai is the southernmost region of Nepal, lies along
the border with India, and is part of the flood plain
of the Ganges River and its tributaries that drain
from the Himalayas to the Bay of Bengal. Sarlahi Dis-
trict is low and flat (approximately 131 m elevation)
with high population density (635/km2) [20]. It is typ-
ical of the entire Indo-Gangetic plain with a popula-
tion of over one billion. It is predominately an area
of traditional, rural, Hindu culture. The population is
mostly peasant farmers (58%) or laborers (26%) and
their families and is considered a poor area in Nepal
with an estimated poverty gap of 0.47 in 2010 [20].
Pregnant women were identified through a baseline
survey of all households at the start of the first trial and
subsequently through 5-weekly follow-up of households
where women of reproductive age resided. Pregnancy
was documented using commercially-available urine
pregnancy tests. Only one pregnancy per woman wasenrolled. The following pregnant women were excluded
in both trials:
 Women who did not intend to deliver their child
within the 9 VDCs in the study area.
 Women who had already received the current
influenza vaccine.
 Women who were allergic to any component of the
vaccine. This exclusion was mostly related to
allergies to eggs.
 Women who refused to provide consent.
 Women who were later than 34 weeks gestation at
the time their pregnancy was identified by the study.
 Women will be excluded from the analysis of
primary outcomes if they deliver their child less
than 2 weeks following receipt of the vaccine or
placebo.
Two sequential annual cohorts of pregnant women
were enrolled into independent trials.
In addition to the exclusions listed above, women
who participated in the first trial were not eligible for
the second trial.
Eligibility Phase 1: Women who were pregnant and
between 17 and 34 weeks gestation at the time of trial
enrollment for the period April 25, 2011 through April
24, 2012 were eligible for participation in the first trial
if they were not excluded based on the above
mentioned exclusion criteria.
Eligibility Phase 2: Women who were pregnant and
between 17 and 34 weeks gestation at the time of trial
enrollment for the period April 25, 2012 through April
24, 2013 were eligible for participation in the second
trial if they did not meet exclusion criteria and if they
had not participated in the first trial.
The date of trial enrollment for both phases was
defined as the day they presented to the vaccination
clinic and were randomized.
Intervention
The intervention tested in these trials was year-round
immunization of pregnant women between 17 and 34
weeks gestation with a commercially available, trivalent
inactivated influenza vaccine licensed in Nepal. Vaxigrip
vaccine (Sanofi Pasteur Ltd.) was used and purchased by
the project from the Yetichem Group in Kathmandu,
Nepal, which sourced the vaccine from Sanofi India,
Mumbai. The vaccine was the current vaccine at the
time of enrollment for an individual woman. That is,
women were scheduled to receive the most up-to-date
influenza vaccine at the time they were enrolled. After
the regular change in vaccine, the vaccine was switched
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and formulations of the trivalent vaccines used through-
out both study periods. The control group received pla-
cebo (saline injection).
Women who were in their first trimester of pregnancy
(<17 weeks) at the time of pregnancy identification had
their enrollment delayed until after 17 weeks. In both
groups, tetanus toxoid (TT) immunization status was
assessed and if a woman failed to report a history of ad-
equate immunization (i.e. 2 doses during the current
pregnancy or 5 total prior doses during her reproductive
years), TT was provided in the opposite arm at the same
time as the study vaccine (influenza/placebo).
The timing of vaccine delivery differed in the two
trials. In the first trial, women were enrolled and vac-
cinated as soon as they were identified as pregnant
and were between 17 and 34 weeks gestation. In the
second trial, after pregnancy identification, women
were randomly assigned to a week of gestation for
enrollment and vaccination that ranged from 17
weeks (or their gestational age at the time of preg-
nancy identification, which ever was later) to 34
weeks. Vaccine was administered by unmasked study
nurses in clinics and homes; these nurses did not par-
ticipate in the weekly illness assessment of the
mother or infant. Mothers and other staff/investiga-
tors were masked. At the conclusion of the study, all
women randomized to placebo were offered influenza
vaccine.
Vaccine and placebo were transported from the sup-
plier in Kathmandu to the field, and from the field
study office to vaccination clinic locations in moni-
tored coolers with continuous temperature tracking.
Any vaccine not kept within the manufacturer’s
recommended temperature range prior to use was
discarded.Table 1 Vaccines used by date
Vaccine formulation Vaccine strains
A/H3N2 A/H1N1
Northern 2010-2011 Perth California
Southern 2011 Perth California
Northern 2011-2012 Perth California
Southern 2012 Perth California
Northern 2012-2013 Victoria California
Southern 2013 Victoria CaliforniaOutcomes
There were 3 primary and several secondary outcomes
for these trials.
Primary outcomes
1. The incidence of laboratory confirmed influenza
illness episodes in the infant through 6 months of
age.
2. The incidence of low birthweight among newborn
infants.
3. Incidence of influenza-like febrile illness (ILI)
episodes of the mother during pregnancy and
through 6 months postpartum.
Signs and symptoms were ascertained during weekly
home visits from the time of maternal enrollment
through 180 days following delivery. Every week, field
staff visited the home and asked about a series of
signs and symptoms for each day in the prior week.
For both pregnant and post-partum women, these
included fever, persistent cough, sore throat, nasal
congestion, myalgia and diarrhea. For infants, these
included high fever, cough, difficult or rapid breath-
ing, rhinorrhea, wheeze, dripping ear, diarrhea, diffi-
culty feeding, jaundice and receipt of immunizations.
We also ascertained if care was sought for any illness
and the type of provider consulted. If a woman or
infant had signs/symptoms included in our defini-
tions, a single sterile nasopharyngeal swab with a
nylon flocked tip (Copan Diagnostics, Murrieta, CA)
was inserted into a nare approximately one-half the
distance between the external nostril and the nasal
bridge and twisted 360° to obtain a mid-nasal respira-
tory specimen. It was then placed in Primestore






Brisbane(V) G7142 24 Apr 11 to 29 Jul 11
Brisbane(V) H9100 7 Aug 11 to 30 Dec 11
Brisbane(V) H7099-1 1 Jan 12 to 31 May 12
H7116-2 1 Jun 12 to 29 Jun 12
Brisbane(V) J7025-1 1 Jul 12 to 15 Oct 12
Wisconsin(Y) J7186-1 15 Oct 12 to 30 Dec 12
Wisconsin(Y) J7154-4 30 Dec 12 to 27 Jan 13
J7217-1 27 Jan 13 to 21 May 13
K7021-3 21 May 13 to 3 Sept 13
K7209-3 3 Sept 13 to 9 Sept 13
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off prior to closing the tube. The test tube was stored
at room temperature for up to one week before being
transported to the local laboratory. In a subsample of
participants, an additional nasal swab was collected
from the other nare and placed in viral culture
medium.
Definitions
 Laboratory Confirmed Influenza in Infants: An
episode of respiratory illness (with one of more of
the following: reported or measured fever (axillary
temperature >38°C), cough, wheeze, difficult or
rapid breathing, or draining ear plus a positive
laboratory test for influenza from nasal swab(s).
 Low birthweight (LBW) in newborn infants: The
internationally accepted definition <2500 g was
considered to be LBW. Eligible weights were those
measured within 72 h of delivery. A secondary
analysis included a back calculation to the weight at
the time of delivery for all infants based on a
statistical model developed from longitudinal
weight measures from newborns included in a
previous study in this population.
 Influenza-Like Illness in Mothers (ILI): The CDC
definition of ILI was used that requires reported or
measured fever (axillary temperature >38°C) plus
either cough or sore throat on one or more days.
Episodes of influenza-like illness were required to be
separated by 7 or more symptom-free days. Laboratory-
confirmed influenza for both mothers and infants is not
simply a subset of ILI, as ILI required fever as part of
the definition and respiratory samples were obtained
using a broader definition. This broader clinical defin-
ition of signs and symptoms included in the definition
for laboratory confirmed influenza reflects the need to
identify cases of influenza with a lower severity of clin-
ical signs and symptoms than that included with ILI.
Secondary outcomes
1. The incidence of clinic visits and hospitalizations for
mothers and infants. These were recorded on the
weekly morbidity forms and linked to episodes of ILI
or respiratory illness.
2. The incidence of ILI and influenza illness in family
members. Definitions for ILI and laboratory
confirmed influenza will be the same as for mothers
and children. Definitions for adults and children
5 years or older will use the maternal definitions.
Definitions for children less than 5 years will use the
infant definitions.3. The incidence of ILI in Infants.: We will use a
modified CDC definition of influenza-like illness for
the infants, including reported or measured fever
(axillary temperature >38°C) plus cough, or draining
ear, or difficulty breathing occurring on one or more
days [2].
4. The incidence of laboratory-confirmed influenza in
mothers. This required an episode of respiratory
illness (reported or measured fever (axillary
temperature >38°C) plus one or more of the following:
cough, sore throat, runny nose, nasal congestion, or
myalgia), in addition to a positive laboratory test for
influenza from a nasal swab.
5. Gestational age. Defined as the difference between
the date of birth and the date of the start of the
woman's last menstrual period (LMP). LMP was
assessed at the time pregnant women were
identified. Preterm birth was defined as gestational
age <37 completed weeks at the time of delivery.
6. Small-for-Gestational-Age. Infants born small-for-
gestational-age were those infants born below the
10th percentile of weight for gestational age [21].
7. Growth. Attained growth was measured at 6
months of age in all enrolled infants. Weight,
length, and head circumference were measured
and weight-for-age, length-for-age, and weight-for-
length Z scores were calculated based on the
WHO growth standards [22].
8. Causes of Febrile Illness: Causes of ILI and
respiratory infections were defined based on
virologic and pertussis assays taken from nasal
swabs.
Randomization
Pregnant women were individually randomized to either
intervention or control at the time of enrollment. Enroll-
ment was defined as the date on which the women was
randomized and received her assigned “treatment”. In
phase 1 (April 25, 2011 – April 24, 2012) vaccination was
scheduled as soon as possible after 17 weeks gestation or
at 17 weeks if the pregnancy was identified prior to 17
weeks. Randomization was stratified by VDC and gesta-
tional age (GA) (two strata 17–25 weeks, 26–34 weeks) in
blocks of size 8. In phase 2 (April 25, 2012 - April 24,
2013), randomization was stratified by VDC and gesta-
tional age (GA) (two strata 17–25 weeks, 26–34 weeks)
and in blocks of size 8. For both phases, individual enve-
lopes were prepared with a sequential serial number on
the outside of a sealed envelope (separate set of ordered
envelopes for each VDC-Gestational Age stratum in both
phases and the treatment assignment for that participant
was printed on a piece of paper inside the envelope).
When a woman of child-bearing age was identified as
pregnant, she was given an appointment date to be
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Upon arrival at the clinic, she had her eligibility recon-
firmed and then was listed on a sequential vaccination
receipt log specific to her VDC-Gestational Age stratum.
Once in the vaccination room, the assigned sealed enve-
lope was opened and she received the treatment (code A,
B C, or D) found inside. At the clinic, vaccine and placebo
were pre-coded and the appropriate vaccine was provided
to the participant based on the code contained in her pre-
numbered envelope.Data collection
The timing of data collection activities is outlined in
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A census of all households in the study area was con-
ducted as a part of phase 1 in order to identify all mar-
ried women age 15–40 years for recruitment, obtain
informed consent for participation, and to collect basic
information about the household and its structure. Basic
information was recorded on age, date of birth, marital
status, and pregnancy status for all married women of
reproductive age.Pregnancy Identification
Initial identification of pregnant women occurred at the
baseline household visit prior to phase 1. Subsequently,
all married women between 15 and 40 years of age wereonthly
uring
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period in the preceding 5 weeks. If the woman had her
period, the week of the period was recorded and she was
visited again 5 weeks later. If she reported no menstrual
period, she was offered a urine-based pregnancy test at
her home. If the test was positive, she received a preg-
nancy enrollment interview that included her reproduct-
ive history, morbidity in the previous month, date of her
last menstrual period, tobacco and alcohol use, and
plans for where and by whom she would deliver her
baby. We also measured her weight, height, blood
pressure, temperature and pulse. Pregnant women were
encouraged to attend antenatal care clinics in the public
or private sector and to deliver at a certified birthing
facility. The study provided education on nutrition, clean
delivery, and danger signs at this visit. We also provided
her with 90 days of iron-folic acid supplements, a clean
birthing kit (included a clean blade, string, plastic tarp,
and small plastic disc on which to cut the cord), chlor-
hexidine ointment for umbilical cord antisepsis, and a
single dose of albendazole.
We visited all women monthly throughout their preg-
nancy to collect pregnancy-related morbidity in the pre-
vious month ask about tobacco and alcohol use, and to
measure weight, blood pressure, pulse, and temperature.
At the time of pregnancy identification, information
on household characteristics was collected and included
measures of household socioeconomic status using an
asset index, ethnicity, total number of persons in the
household, house construction materials and size, source
of drinking water, household sanitation practices, type of
fuel used for cooking, and whether there were members
of the household working outside the local area or coun-
try. A complete household roster was also completed at
this time including information on age, date of birth,
sex, marital status, literacy, educational level, and
tobacco use for each member of the household.
Trial enrollment visit
Enrollment/vaccination visits occurred at a central loca-
tion in the VDCs on a rotating basis. Upon arrival at the
clinic site, consent to participate was reconfirmed with the
woman, her TT history was collected, and a short inter-
view was conducted to reconfirm eligibility. She was listed
on the sequential vaccine receipt log and the vaccinator
was provided the sealed envelope that matched her serial
number. She was subsequently immunized with her
assigned treatment in a private location by an unmasked
study vaccinator.
Pregnancy outcome assessment
When a baby was born, the family contacted a local staff
member as soon as possible, often during labor. Project
staff then visited the home to collect extensiveinformation on the birth process and the health of the
mother and newborn infant(s). Weight, length, head cir-
cumference, and temperature of the infant(s) were mea-
sured and recorded. One week following delivery, a visit
was made to record information on maternal post-
partum morbidity.
Respiratory morbidity assessment
All women and their newborn infants were visited weekly
for morbidity assessment as described previously. Women
were visited during pregnancy and through 6 months
post-partum. Infants were visited through 6 months of
age. Once a woman and her infant reached 180 days post-
partum they were discharged from the study.
Cause of death assessment
All women and children who died were identified and a
verbal autopsy was conducted with members of the family
after a culturally appropriate mourning period.
Laboratory procedures
Mid-nasal specimens were collected using nylon flocked
swabs and placed in 1.5 mL of Primestore transport
medium, as described. Following local storage at ambient
temperature for up to one week, tubes were shipped to
the local laboratory, aliquotted into cryovials with
secure seals, and stored in a refrigerator prior to shipment
at room temperature to the University of Washington
Molecular Diagnostics Laboratory, where the samples
were stored at −80°C. For PCR analysis, total nucleic acids
were extracted from 200 μL of Primestore as described for
nasal washes [23] and tested for influenza A and B RNA
using real-time reverse transcription (RT)-PCR targeting
the influenza A and B matrix genes [24]. Specimens posi-
tive for influenza A were subtyped for the seasonal influ-
enza A H1 and H3 subtypes and the novel 2009 H1N1
subtype using real time RT-PCR assays, which employ
primers and TaqMan probes that target the specific sub-
type hemagglutinin genes. Extracted nucleic acid samples
were added to a commercial master mix (UltraSense One-
Step RT-PCR kit, Invitrogen) containing the forward and
reverse primers and the probe in a final volume of 40 μL.
RT-PCR cycling conditions are according to the manufac-
turer’s recommendations for a total of 40 cycles. Positive
and negative controls consisting of uninfected human cells
and clinical specimens confirmed positive for each influ-
enza A subtype by the Washington State Public Health
Laboratory were included in each extraction and PCR run.
Samples were considered positive for influenza A or B if
the PCR amplification plots crossed the threshold before
cycle 40. Each assay had a 95% limit of detection of 10
copies per reaction or 500 copies per swab.
Assays were also conducted for other respiratory path-
ogens including pertussis and respiratory viruses on a
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[24,25]. Nasal swabs for culture were collected in UTM
Viral Transport Media (Copan Diagnostics, Inc.,
Murrieta, CA). These tubes were kept in a cooler box
after collection and subsequently stored in liquid N2 in
the field laboratory and transported to Cincinnati where
they were stored at −70°C.
Maternal blood was collected using venipuncture into
sterile vacutainers. These tubes were kept in a cooler
box and transported to the field laboratory. Umbilical
cord blood was collected in sterile urine cups by milking
the cut umbilical cord. All blood samples were spun, the
serum drawn off and then aliquoted prior to storing in
liquid N2. Serum samples were transported to Cincinnati
where they were stored at −70°C.
The serum analysis for antibodies was performed by
the Laboratory for Specialized Clinical studies at Cincin-
nati Children’s Hospital. This lab is certified by the
Clinical Laboratory Improvement Amendments (CLIA)
and the College of American Pathologists (CAP). Sera
were first assessed for antibody to each of the three
components of the vaccine by hemagglutination inhib-
ition (HAI) assay using standard methods [26-28]. In
brief, sera were treated with Receptor-Destroying
Enzyme (RDE; Denka-Seiken, Japan) to remove non-
specific inhibitors of hemagglutination prior to testing.
Following RDE treatment, the samples were further
diluted to 1:10 in Phosphate Buffered Saline (PBS). The
sera were then treated with turkey packed red blood
cells (RBCs) to remove non-specific agglutinins. The
RBCs were spun out of the sera and the samples were
ready for testing. Starting at 1:10 dilution, the sera were
diluted two-fold through 1:2560 in V-bottom microtiter
plates.
Egg-derived, inactivated viral antigens A/California/7/
2009 (H1N1)pdm09, A/Perth/16/2009(H3N2 and B/
Brisbane/60/2008 (B/Victoria) representative of the
vaccine from 2010 to 2012 and A/California/7/2009
(H1N1), A/Victoria/361/2011 (H3N2 and B/Wisconsin/
1/2010 (from the B/Yamagata lineage of viruses) repre-
sentative of the vaccine from 2012 to 2013 were ob-
tained from the Influenza Reagent Resource (www.
influenzareagentresource.org). The antigens were added
to serially diluted sera, and incubated at room tempera-
ture for 30 minutes. RBCs from turkey blood (Viromed
Laboratories, Minnetonka, MN) were suspended at a con-
centration of 0.5% in PBS, added to the serum/viral anti-
gen mixture, and incubated at room temperature for 30
minutes. Plates were tilted and read. The antibody titers
were reported as the reciprocal of the last serum dilution
to completely inhibit RBC agglutination. Sera without
reactivity were assigned a value of < 10. Sera with initial
titers of ≥ 2560 were retested at a higher starting dilution
in order to obtain a reportable titer. Control sera wereestablished for each antigen and were run in each assay.
The assay was valid if the control sera fell within 2 fold of
their defined titer. The three antigens used in the assay
were shown to be specific by using reference sera supplied
by the CDC before use in the HAI. Microneutrilization
assays were conducted by the Centers for Disease Control
and Prevention according to their standard protocol [29].
Sample size
Sample size requirements were driven by the primary
outcomes for these trials.
All three primary outcomes were considered equivalent
in importance and thus, the Type I error was corrected for
these multiple primary endpoints. We assumed a total
Type I error of 5% across the three primary endpoints,
thus needing a sample size corresponding to one-third of
this value, or 0.017 for each primary outcome.
1. Laboratory Confirmed Influenza Illness in
Infants 0–6 months of age: We assumed a
baseline rate of 21.6/100 person-years based on
the Bangladesh trial [18]. A sample size of 1850
pregnancies (925 in each group) would detect a
50% reduction with 90% power for this endpoint.
2. Low Birthweight: Data on the expected incidence
of low birthweight came from previous studies
we have conducted in this area [30]. The current
best estimate is 30.4/100 live births. With 1850
pregnancies, a 25%-30% relative reduction would be
detected with 90% power.
3. Influenza-Like-Illness in Women in Pregnancy
and through 6 Months Postpartum: We assumed
a baseline rate of 34/100 person-years based on
previous studies in this area [31]. With 1850
pregnancies, a 30% to 35% relative reduction in
incidence was detectable with 90% power.
Data management and analysis
Data were collected on paper forms and checked for
errors and missing values before being sent from the
field site to Kathmandu for data entry. Data entry
screens checked for inconsistencies and out of range
values. Errors were corrected by data supervisors based
on all relevant forms or sent back to the field for clarifi-
cation if not time sensitive data.
Two separate analyses will be conducted for each of
the annual two cohorts of women vaccinated. A consort
diagram will be constructed to show the number of
women enrolled, randomized, pregnancy outcomes and
live born infants, and losses to follow up through 6
months postpartum. A table will show baseline compar-
ability of the two randomized groups using household
and individual maternal level characteristics. The pri-
mary outcomes will be compared using relative risk
Tielsch et al. BMC Pregnancy and Childbirth  (2015) 15:40 Page 9 of 10ratios and 95% confidence intervals. Primary outcomes
may be stratified by time periods where influenza expos-
ure was high, moderate or low.
Ethical review
These trials were reviewed and approved by the Institu-
tional Review Boards at the Johns Hopkins Bloomberg
School of Public Health (USA), the Institute of Medicine
at Tribhuvan University (Nepal), and Cincinnati Children’s
Medical Center (USA) and registered at Clinicaltrials.gov
(NCT01034254). The study was also approved by the
Nepal Health Research Council. An independent Data and
Safety Monitoring Board (DSMB) was formed and was
available to discuss emergent issues if they should arise.
This group met formally once prior to the start of the
study, once approximately mid-way through the first trial,
and is scheduled to meet again in early 2015 to review the
results of both trials.
Discussion
We have provided a description of the design and
methods used in a consecutive pair of community-based,
placebo-controlled, randomized trials of influenza vaccine
in pregnant women on respiratory outcomes in the
mothers and their infants and in the outcomes of preg-
nancy conducted in rural Nepal. Interest is growing in
using maternal immunization as a strategy to protect both
women and their newborns from important infectious dis-
orders, especially early prior to the normal time at which
immunizations are scheduled in infancy. The most recog-
nized model for this approach is immunization of preg-
nant women with tetanus toxoid for prevention of
neonatal tetanus. This has proven to be highly effective
and is a routine practice in almost every country [16]. As
we anticipate the approvals of new vaccines, especially
those against serious respiratory illness in young infants
such as respiratory syncytial virus, the option of immuniz-
ing the mother to transfer protection to her infant in that
vulnerable period of early infancy is becoming more
attractive.
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